目的：分析子宮內膜癌病人接受手術與放射線治療之結果與預後因子。材料與方法：自1993年8月至2004年4月，有69位診斷為子宮內膜癌的病人在本院接受治療。病人的年齡中位數是55歲（範圍從34至80歲）。以FIGO分期系統來訂定病人的癌症期別，46位病人(67%)是stageⅠ，8位(12%)是stage Ⅱ，12位(17%)是stage Ⅲ，3位(4%)是stage Ⅳ。58位病人(84%)的病理組織細胞型態是子宮內膜腺癌，11位(16%)則為子宮內膜腺癌以外的病理細胞型態：在此當中，4位是leiomyoscarcoma，3位是MMMT(malignant mixed mullerian tumor)，2位是papillary serous carcinoma，1位是clear cell carcinoma，1位是mixed mucinous and small cell carcinoma。所有69位病人都接受手術治療，這當中有63位病人(91%)接受術後放射線治療。結果：治療後的追蹤時間中位數是38個月（範圍從8至129個月）。在追蹤的過程中，60位病人(87%)存活，9位病人(13%)死亡。3位病人(4%)有局部復發的情形。9位病人(13%)則有遠端轉移。五年的整體存活率是85%。在單變項分析中，癌症期別對於整體存活率來說是一個重要的預後因子（p值為0.0298）。病理組織細胞型態對於整體存活率來說也是一個重要的預後因子（p值為0.0063）。是否有淋巴結轉移對於整體存活率來說是另一個重要的預後因子（p值為0.0469）。而在多變項分析當中，病理組織細胞型態對於整體存活率來說仍舊是一個重要的預後因子（p值為0.045）。結論：以手術與放射線治療來治療子宮內膜癌病人，在本文研究中可以達到85%的五年整體存活率。癌症期別、病理組織細胞型態與是否有淋巴結轉移，是影響整體存活率的重要預後因子。未來需要更長時間的追蹤以評估病人的治療結果與長期預後。

Purpose: To evaluate the prognostic factors and treatment outcomes in patients of endometrial cancer with treatments of surgery followed by radiotherapy. Materials and Methods: From August 1993 to April 2004, there were 69 patients diagnosed as endometrial cancer at our hospital. The median age at diagnosis was 55 years (ranged from 34 to 80 years). According to the FIGO staging system for cancer of the uterine body, 46 patients (67%) were stage Ⅰ, 8 (12%) were stage Ⅱ, 12 (17%) were stage Ⅲ, and 3 (4%) were stage Ⅳ. Fifty-eight patients (84%) had endometrioid carcinomas and 11 patients (16%) had non-endometrioid carcinomas: 4 were leiomyoscarcomas, 3 were MMMTs (malignant mixed mullerian tumor), 2 were papillary serous carcinomas, 1 was clear cell carcinoma, and 1 was mixed mucinous and small cell carcinoma. All 69 patients underwent surgery. Sixty-three (91%) of these 69 patients received postoperative adjuvant radiotherapy. Results: The median follow-up duration was 38 months (ranged from 8 to 129 months). During the follow-up period, 60 patients (87%) were alive, and 9 patients (13%) died. Three patients (4%) had local recurrence. Nine patients (13%) had distant metastases. The actuarial 5-year overall survival rate was 85%. In univariate analysis, stage was a significant prognostic factor for overall survival, favoring early stages (p=0.0298). Pathological cell type was also a prognostic factor for overall survival, favoring cell type of endometrioid carcinoma (p=0.0063). Lymph node metastasis was another significant prognostic factor affecting overall survival, favoring status without lymph node metastasis (p=0.0469). In multivariate analysis, pathological cell type continued to be a significant prognostic factor for overall survival, favoring cell type of endometrioid carcinoma (p=0.045). Conclusions: The 5-year overall survival rate of 85% was achieved in our report of patients of endometrial cancer treated with surgery followed by radiotherapy. Stage, pathological cell type and lymph node metastasis were significant prognostic factors affecting overall survival based on our study. Longer follow-up of these patients and accrual of more patients are needed to evaluate long-term survival and treatment outcomes.